Literature DB >> 1516305

Heterotopic bone in hip arthroplasties. Cemented versus noncemented.

H J Duck1, A G Mylod.   

Abstract

Sixty-six hip arthroplasties in 55 patients were reviewed to specifically study cemented versus noncemented procedures, as related to heterotopic bone formation (HBF). Other factors considered included the type of arthroplasty, surgical approaches, preoperative and postoperative medicines, preoperative predisposing diagnoses, range of motion, and pain. The overall percentage of heterotopic ossification was 64%. There was no significant difference between cemented (67%) and noncemented (55%) procedures. Except for an increased percentage (80%) of ossification after a trochanteric osteotomy, there were no significant differences between the three reviewed surgical approaches. Male osteoarthritics had the highest overall HBF. Eighty percent of patients who previously had developed HBF also did so with a contralateral hip surgery. Surprisingly, all patients with gout (100%) developed HBF. Acetylsalicylic acid used prophylactically for anticoagulation had no significant effect. Resurfacing arthroplasty procedures accounted for half of the severe grades of HBF. A decreased range of motion occurred with more severe grades of HBF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516305

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Does a plastic drape reduce incidence of heterotopic ossification after hip resurfacing?

Authors:  John S Shields; Ali Mofidi; William G Ward; Riyaz H Jinnah
Journal:  Clin Orthop Relat Res       Date:  2011-06       Impact factor: 4.176

2.  Heterotopic ossification after total hip arthroplasty: our experience.

Authors:  A Spinarelli; V Patella; M Petrera; A Abate; V Pesce; S Patella
Journal:  Musculoskelet Surg       Date:  2011-01-06

Review 3.  Trauma-Induced Heterotopic Ossification Regulates the Blood-Nerve Barrier.

Authors:  Zbigniew Gugala; Elizabeth A Olmsted-Davis; Yuqing Xiong; Eleanor L Davis; Alan R Davis
Journal:  Front Neurol       Date:  2018-06-05       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.